An international team has shown that three injections of bioactive nanoparticles can reverse signs of Alzheimer's in mice by reactivating the blood-brain barrier, the brain's vascular control gate. According to the authors, at the time of administration, a 50-60% drop in amyloid-β in brain tissue.
The research, co-directed by the Institute of Bioengineering of Catalonia (IBEC) and the West China Hospital from Sichuan University, has been published in the journal Signal Transduction and Targeted TherapyAlthough the results are striking, those responsible emphasize that These are animal models and that any clinical application will require further steps.
What this strategy brings
Unlike much of classical nanomedicine, here the particles are not a simple vehicle: act as supramolecular drugs with its own activity. The goal is not to attack the neuron directly, but restore the blood-brain barrier (BBB) so that the vascular system itself can recover its cleansing function.
The brain is a very demanding organ from an energetic point of view, it consumes around 20% of the energy in adults and can reach 60% in children. This demand is sustained by an extraordinarily dense capillary network: it is estimated to be in the order of billion capillaries irrigating and nourishing the neurons.
When the BBB is degraded, the elimination of harmful compounds is impaired. By focusing on repair this interface, the therapy facilitates the crossing of waste proteins into the bloodstream, where the body can eliminate them normally.
In the case of Alzheimer's, the main target is the amyloid-β (Aβ), whose accumulation alters neuronal communication and is associated with progressive cognitive deterioration.
How it works: BBB and the LRP1 pathway
Under physiological conditions, protein LRP1 It is key to recognizing Aβ and transporting it across the BBB into the bloodstream. However, this system is delicate: if the binding is too strong and massive, transport stalls and LRP1 degrades; if it's weak, the signal isn't sufficient to activate the process.
The designed nanoparticles mimic LRP1 ligands and offer a multivalent interaction which optimizes the passage of Aβ without collapsing the system. In this way, the natural evacuation route is reactivated and the toxic load is reduced in the brain parenchyma.
The team employed a bottom-up molecular engineering, precisely controlling the particle size and number of ligands on its surface. This fine-tuning allows for modulation of membrane receptor trafficking and directing the biological response with greater specificity.
According to the authors, the restoration of the vasculature triggers an effect on waterfall: By clearing Aβ and other harmful molecules, the BBB regains its balance and the brain itself resumes its homeostasis.
Study design in mice
To test the hypothesis, we used transgenic mice with Aβ overproduction and marked cognitive impairment. The protocol consisted of the administration of three doses of supramolecular drugs and functional and biochemical monitoring for months.
The first milestone was immediate: at the injection time A 50-60% reduction in Aβ levels in the brain was detected. Subsequently, in memory and behavioral tests, the animals showed sustained improvement.
In an illustrative case, a mouse 12 months (approximately the equivalent of 60 years in humans) received the treatment and, six months later, its behavior resembled that of a healthy mouse, despite already being at an advanced stage (18 months).
The authors emphasize that these age equivalencies are indicative and that, as a precaution, should not be extrapolated directly to people without specific tests.
Who signed and where it was published
The project is co-directed by IBEC (Barcelona) and the West China Hospital of Sichuan University, with the participation of UCL and teams from the United Kingdom and China, as well as researchers linked to the University of Barcelona and ICREA.
The work appears in Signal Transduction and Targeted Therapy under the title focused on the modulation multivalent transport across the BBB. The article identifier (DOI) reported by the authors is 10.1038/s41392-025-02426-1.
Implications and next steps
The results open a promising path to address the vascular contributions of Alzheimer's and could complement treatments that currently only slow the decline. However, the move to clinical trials requires demonstrate safety and efficacy in humans.
Specialists outside the study are cautious: it is a significant advance, but preliminaryReproducibility will need to be validated, dosage and schedule adjusted, and potential long-term effects studied before considering patient trials.
If the next phases confirm what has been observed, this approach could rethinking therapeutics Alzheimer's by focusing on the BBB as a purification system and not just on attacking the amyloid plaque directly.
The data suggest that repairing the blood-brain barrier with custom-designed nanoparticles can rapidly reduce amyloid-β, restore cognitive function in mice, and trigger a cascading effect that stabilizes the vasculature; a line of work with potential, but which has yet to fully complete the regulatory and clinical path.